<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022186</url>
  </required_header>
  <id_info>
    <org_study_id>65/06-02-2021</org_study_id>
    <nct_id>NCT05022186</nct_id>
  </id_info>
  <brief_title>The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment</brief_title>
  <official_title>Comparative Randomized Clinical Trial of the Efficacy of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment and APOE ε4 Carriers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Greek Alzheimer's Association and Related Disorders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Clinical Trial that will compare the effects of Cannabidiol and Homotaurine in&#xD;
      cognition and mental health in patients with Mild Cognitive Impairment and APOE ε4 carriers.&#xD;
      Ninety patients will be recruited and they will be randomly distributed in three groups. The&#xD;
      first group will receive treatment with Cannabidiol 5%, the second group will receive&#xD;
      treatment with Vivimind and the third group will not receive any treatment. The three groups&#xD;
      will be compared by using an extensive neuropsychological examination and biomarkers' results&#xD;
      from cerebrospinal fluid and blood&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Mini Mental State Examination (MMSE) score</measure>
    <time_frame>12-24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Montreal Cognitive Assessment (MoCA) score</measure>
    <time_frame>12-24 months</time_frame>
    <description>Screening test to assess general cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Functional Cognitive Assessment (FUCAS) score</measure>
    <time_frame>12-24 months</time_frame>
    <description>Measurement of daily functionality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Letter &amp; Category Verbal Fluency</measure>
    <time_frame>12-24 months</time_frame>
    <description>Measurement of verbal fluency, learning, long term memory and categorization skills</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Clinical Dementia Rating Scale score</measure>
    <time_frame>12-24 months</time_frame>
    <description>Measurement of general cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in ADAS-COG</measure>
    <time_frame>12-24 months</time_frame>
    <description>Measurement of general cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Rey Auditory Verbal Learning Test</measure>
    <time_frame>12-24 months</time_frame>
    <description>Screening tool to assess verbal memory and learning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Rey Osterrieth Complex Figure</measure>
    <time_frame>12-24 months</time_frame>
    <description>Screening tool to assess visuospatial memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Functional Rating Scale for Dementia</measure>
    <time_frame>12-24 months</time_frame>
    <description>Measurement of daily functionality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Trail Making Test A &amp; B</measure>
    <time_frame>12-24 months</time_frame>
    <description>Screening tool to assess working memory and processing speed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Geriatric Depression Scale</measure>
    <time_frame>12-24 months</time_frame>
    <description>Screening tool to assess depressive symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in SAST</measure>
    <time_frame>12-24 months</time_frame>
    <description>Screening tool to assess anxiety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Beck Anxiety Inventory</measure>
    <time_frame>12-24 months</time_frame>
    <description>Screening tool to assess anxiety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Rivermead Behavioural Memory Test</measure>
    <time_frame>12-24 months</time_frame>
    <description>Screening tool to assess episodic memory and learning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in STROOP Test</measure>
    <time_frame>12-24 months</time_frame>
    <description>Measurement of selective attention and cognitive flexibility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Symbol-Digit Test</measure>
    <time_frame>12-24 months</time_frame>
    <description>Measurement of processing speed, learning and working memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in BDNF</measure>
    <time_frame>12-24 months</time_frame>
    <description>Cerebrospinal Fluid Biomarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in MDA</measure>
    <time_frame>12-24 months</time_frame>
    <description>Cerebrospinal Fluid Biomarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in GFAP</measure>
    <time_frame>12-24 months</time_frame>
    <description>Cerebrospinal Fluid Biomarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Tau-protein</measure>
    <time_frame>12-24 months</time_frame>
    <description>Cerebrospinal Fluid Biomarker</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Group receiving Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will receive cannabidiol 5% without other medication for cognition and depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group receiving Homotaurine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will receive Vivimind (homotaurine) without other medication for memory and depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These patients will not receive treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol Oil</intervention_name>
    <description>Patients will use it with specific instructions and they will be monitored at least one time in a month</description>
    <arm_group_label>Group receiving Cannabidiol</arm_group_label>
    <other_name>CBD 5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Homotaurine</intervention_name>
    <description>Patients will use it with specific instructions and they will be monitored at least one time in a month</description>
    <arm_group_label>Group receiving Homotaurine</arm_group_label>
    <other_name>Vivimind</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Mild Cognitive Impairment&#xD;
&#xD;
          -  Carry APOE ε4 gene&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Dementia&#xD;
&#xD;
          -  Patients who receive medication for memory or depression&#xD;
&#xD;
          -  Patients who do not carry APOE ε4 gene&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thanos Chatzikostopoulos, MSc</last_name>
    <phone>6988605949</phone>
    <email>thachatziko@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Greek Association of Alzheimer's Disease and Related Disorders</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54248</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanos Chatzikostopoulos, Psychologist, MSc</last_name>
      <phone>6988605949</phone>
      <email>thachatziko@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Magda Tsolaki, Neurologist, Professor</last_name>
      <email>tsolakim1@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Magda Tsolaki</investigator_full_name>
    <investigator_title>Professor of Neurology, Medical School, Aristotle University of Thessaloniki</investigator_title>
  </responsible_party>
  <keyword>cannabidiol</keyword>
  <keyword>homotaurine</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Cognition</keyword>
  <keyword>Mental Health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
    <mesh_term>Tramiprosate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participants' personal data will not be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

